GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
NewLink Genetics Corp (NLNK) [hlAlert]

Rating:
Buy NLNK
up 218.11 %

NewLink Genetics Corp (NLNK) rated Buy with price target $55 by Stifel

Posted on: Friday,  Nov 7, 2014  10:25 AM ET by Stifel

Stifel rated Buy NewLink Genetics Corp (NASDAQ: NLNK) on 11/07/2014. Previously Stifel rated Buy NewLink Genetics Corp (NASDAQ: NLNK) on 05/07/2013.,
when the stock price was $14.63. Since then, NewLink Genetics Corp has gained 218.11% as of 01/07/2016's recent price of $46.54.
If you would have followed the previous Stifel's recommendation on NLNK, you would have gained 218.11% of your investment in 975 days.

NewLink Genetics Corporation (NewLink) is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung) and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma).

Stifel
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/7/2014 10:25 AM Buy
None
31.99 55.00
as of 10/17/2014
1 Week up  61.88 %
1 Month up  8.74 %
3 Months up  44.79 %
1 YTD up  33.34 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/22/2014 8:25 AM Buy
None
34.26 53.00
12/13/2013 9:25 AM Buy
None
22.18 31.00
8/8/2013 8:25 AM Buy
None
17.73 28.00
5/7/2013 9:25 AM Buy
None
14.63 25.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy